Table 3. CEA and ROI analysis at Different Prices of PCSK9 (Health System’s and Payer’s Perspective) 1/.
| PCSK9 inhibitor price | Perspective | ||
|---|---|---|---|
| Health System | Payer 2/ | ||
| ICER | ROI | NPV | |
| $500 | $4,103 | 39.8% | $495 |
| $1,000 | $16,870 | -55.5% | -$2,167 |
| $2,500 | $55,170 | -85.4% | -$10,156 |
| $5,000 | $119,004 | -93.1% | -$23,469 |
| $7,500 | $182,838 | -95.5% | -$36,783 |
| $10,000 | $246,673 | -96.6% | -$50,096 |
| $12,500 | $310,507 | -97.3% | -$63,410 |
| $14,000 | $348,807 | -97.6% | -$71,398 |
| $15,000 | $374,341 | -97.8% | -$76,723 |
| Breakeven prices | |||
| $593 | $6,478 | 0.0% | $0 |
| $4,256 | $100,000 | -91.8% | -$19,506 |
1/ Effect of PCSK9 inhibitors on annual probability of CVD is obtained directly from the 1 year effect study of evolocumab.
2/ Private insurance perspective assuming national average premiums, medication copayments and deductibles. It also includes a health insurance turnover rate of 12%.
ICER = Incremental cost-effectiveness ratio. ROI = Return on investment. NPV = Net present value.